---
category: news
title: "Lantern Pharma’s New Drug Candidate for Mantle Cell Lymphoma Shows Promise"
excerpt: "The Dallas-based biopharmaceutical company expects to begin testing the drug candidate in a “first in human” trial in mid-2023. The drug was developed using the publicly traded company’s AI/ML drug development platform."
publishedDateTime: 2022-12-23T00:08:00Z
originalUrl: "https://dallasinnovates.com/lantern-pharmas-new-drug-candidate-for-mantle-cell-lymphoma-shows-promise/"
webUrl: "https://dallasinnovates.com/lantern-pharmas-new-drug-candidate-for-mantle-cell-lymphoma-shows-promise/"
type: article
quality: 22
heat: -1
published: false

provider:
  name: Dallas Innovates
  domain: dallasinnovates.com

topics:
  - AI in Healthcare
  - AI

images:
  - url: "https://s24806.pcdn.co/wp-content/uploads/2022/12/Panna-Sharma_Lantern-Pharma.jpg"
    width: 970
    height: 465
    isCached: true

related:
  - title: "Pharma firm makes RSV vaccine candidate breakthrough with artificial intelligence"
    excerpt: "Biopharmaceutical firm Poolbeg Pharma has found a number of RSV vaccine candidates via artificial intelligence (AI), in a landmark move in finding a"
    publishedDateTime: 2022-12-21T09:21:00Z
    webUrl: "https://www.cityam.com/pharma-firm-makes-rsv-vaccine-candidate-breakthrough-with-artificial-intelligence/"
    ampWebUrl: "https://www.cityam.com/pharma-firm-makes-rsv-vaccine-candidate-breakthrough-with-artificial-intelligence/?amp=1"
    cdnAmpWebUrl: "https://www-cityam-com.cdn.ampproject.org/c/s/www.cityam.com/pharma-firm-makes-rsv-vaccine-candidate-breakthrough-with-artificial-intelligence/?amp=1"
    type: article
    provider:
      name: City A.M.
      domain: cityam.com
    quality: 54
    images:
      - url: "https://www.cityam.com/wp-content/uploads/2021/10/1219071027.jpg"
        width: 1024
        height: 683
        isCached: true

secured: "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;Vmuv3YXDcHAtYAAOiTKpGw=="
---

